Serenex, Inc., a leader in the discovery and development of small molecule Heat Shock Protein 90 (Hsp90) inhibitors, today announced the signing of a Materials Cooperative Research and Development Agreement (M-CRADA) with the National Cancer Institute (NCI) at the National Institutes of Health (NIH). Under this M-CRADA, Dr. Leonard Neckers and his colleagues at the NCI will assess Serenex’s novel, small molecule, orally bioavailable Hsp90 inhibitor SNX-5422 as a potential therapeutic for non-small cell lung cancer.